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ABSTRACT 
Context: Post-market evidence generation for medical devices is important yet limited for 32 
prosthetic aortic valve devices in the United Kingdom (UK). 
Objective: To identify prosthetic aortic valve models that display unexpected patterns of 34 
mortality or re-intervention using routinely collected national registry data and record linkage. 
Design: Observational study using the UK National Adult Cardiac Surgery Audit (NACSA) 36 
registry for procedures performed between 1998 and 2013. Valves were classified into series of 
related models. Outcome tracking was performed using multifaceted record linkage. The median 38 
follow-up was 4.1 years (maximum 15.3 years). Cox proportional hazards regression with 
random effects (frailty models) were used to model valve effects on the outcomes, with and 40 
without adjustment for (pre-)operative covariates. 
Setting: All National Health Service and private hospitals in England and Wales who submit 42 
data to the NACSA registry. 
Patients and Interventions: All patients undergoing first-time elective and urgent aortic valve 44 
replacement surgery (± coronary artery bypass graft) with a mechanical (n=10 series) or 
biological (n=15 series) prosthetic valve from 5 primary suppliers, and satisfying pre-specified 46 
data quality criteria were included (n=43,782 biological, n=11,084 mechanical). 
Main Outcome Measures: Time to all-cause mortality or aortic valve re-intervention (surgical 48 
or trans-catheter). There were 13,104 deaths and 723 re-interventions during follow-up. 
Results: Two series of valves were associated with significantly increased hazard of death or re-50 
intervention were identified: Sorin Biological Series (frailty 1.18 [95%PI: 1.06 to 1.32]) and 
 4 
Sorin Mitroflow series (frailty 1.19 [95%PI: 1.09 to 1.31]). These results were robust to covariate 52 
adjustment, and sensitivity analyses. Three biological valve series were associated with 
significantly decreased hazard. 54 
Conclusions: Meaningful evidence from the analysis of routinely-collected registry data can 
inform post-market surveillance of medical devices. Although the findings are associated with a 56 
number of caveats, two specific biological aortic valve series identified in this study may warrant 
further investigation. 58 
Word count (abstract): 300 
Keywords: Post-market surveillance; prosthetic valves; aortic valves; survival; clinical registry 60 
data 
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INTRODUCTION 
In recent years there has been a shift in emphasis from establishing device safety and 64 
effectiveness before marketing, to post-market evidence generation and surveillence.1 The 
United States Food and Drug Administration (US FDA) system for post-market surveillance has 66 
been found to be in need of strengthening.2,3 This need for improved surveillance systems was 
recently highlighted by the international health scare caused by Poly Implant Prothèse (PIP) 68 
breast implants.4 Post-market surveillance systems have historically been reactive rather than 
proactive in the United Kingdom (UK) as evidenced by concerns over hip prostheses leading to 70 
the UK National Joint Registry being established.5 
Prosthetic heart valves have evolved significantly since the first valve replacement was 72 
performed in 1952. Although there are two main groups of prosthetic heart valve, tissue or 
mechanical, there are a variety of different valves within these groups. There is a large body of 74 
literature on the long-term reliability of prosthetic heart valves, but these studies, whether 
randomised trials,6 observational,7 or case-series,8 typically compare a very small number of 76 
valves. Data from systematic benchmarking of long-term performance is not readily available.  
In the UK, the Heart Valve Registry (UKHVR) was established in 1986 between the 78 
Government’s Department of Health and the Society for Cardiothoracic Surgery in Great Britain 
and Ireland (SCTS).9,10 Within 10-years a minimum dataset of clinical variables about heart 80 
valve replacement procedures had been entered for more than 45,000 patients.11 The UKHVR 
fulfilled an important role: the ability to monitor trends in outcomes by different prosthetic valve 82 
models. It was setup to do this by recording valve model and serial numbers for implanted 
prosthetic valves, and also by linkage to mortality data, including cause of death, from the Office 84 
 6 
for National Statistics (ONS). In 2004, funding was withdrawn due to cost and governance 
issues, with its functionality partly subsumed by a national adult cardiac surgery register.12 86 
Currently, the UK agency responsible for ensuring that medical devices meet applicable 
standards of safety – the Medicines and Healthcare products Regulatory Agency (MHRA) – 88 
collects data on acute valve failures submitted by healthcare professionals; however, in the 
absence of a device-specific registry, the opportunity to detect patterns of unexpected outcomes 90 
are limited. 
Prospective surveillance based on clinical registries that record device-specific 92 
information can identify important signals that passive reporting mechanisms may miss,13,14 and 
there have been calls to move from reactive to proactive monitoring.14 As a prelude to any 94 
prospective surveillance programme, we present results for a retrospective cross-sectional 
surveillance analysis of prosthetic valves implanted into patients undergoing aortic valve 96 
replacement (AVR) surgery with or without concomitant coronary artery bypass grafting 
(CABG) in England and Wales over the past 15-years. 98 
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MATERIALS AND METHODS 100 
Extraction and preprocessing of aortic valve surgery data 
A complete extract from the National Adult Cardiac Surgery Audit (NACSA) registry 102 
version 4.1.2), which is run by the National Institute for Cardiovascular Outcomes Research 
(NICOR; an institute of University College London), was performed on 10th October 2014. This 104 
extract included all adult cardiac surgery procedures performed in UK National Health Service 
(NHS) hospitals, some private hospitals and some hospitals in the Republic of Ireland. Case 106 
ascertainment of NHS procedure is expected to be high for most of the study period.12 As part of 
a wider clinical epidemiological research and quality improvement programme, a regularly 108 
updated suite of ‘data cleaning’ rules developed by specialist clinicians were coded and applied 
to the raw data (excluding the valve model data) prior to any analysis as summarized in the 110 
Appendix.15,16 
The initial filtering step was to extract all records corresponding to aortic valve surgery 112 
performed in hospitals located in England and Wales between 1st April 1998 and 31st March 
2013. Data for one private hospital were removed prior to analysis pending local validation, as 114 
were all data for patients who had more than one record in the registry for the same admission 
spell. For the purposes of this study, we selected all patients who underwent an AVR ± CABG. 116 
We then excluded all records corresponding to: 1) patients having previous cardiac surgery; 2) 
suspected incorrectly entered trans-catheter aortic valve implantation (TAVI) procedures (as 118 
identified using a rules-based approach); 3) emergency or salvage procedures; 4) unidentifiable 
responsible consultant surgeon (as identified by a unique surgeon’s General Medical Council 120 
number in the registry); 5) missing primary outcome data. 
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Record linkage 122 
To facilitate long-term monitoring of patient and valve status, we performed multiple 
record linkages for each patient for life status, surgical reoperation, and TAVI as described in the 124 
Appendix. 
Valve model data and data quality 126 
Prostheses are recorded in the NACSA registry in two separate free-text fields: valve 
name and valve model. There was inconsistency on how each hospital entered these data. An 128 
updated suite of data-processing scripts was written to map each recorded name and/or model to 
a homogenous list of known prosthetic valves using a variety of information sources as described 130 
in the Appendix. For each record, we attempted to record the valve manufacturer, model, series, 
and type (mechanical or biological, and xenograft type in the case of biological valves). Here, 132 
‘series’ refers to a group of valve models from a single manufacturer considered related (See 
Table S1 for groupings used). Not all valves could be accurately classified. When valve series 134 
was not clear, a subjective decision was made based on expert clinical opinion. Note that 
manufacturer classification only reflects ownership as of 2015 to the best of our knowledge. 136 
Some models have been acquired by manufacturers through business mergers and acquisitions, 
but are grouped together according to model. 138 
Records which were irrelevant or featured gross inconsistencies were excluded, including 
records that could either not be matched or which were matched to more than one manufacturer, 140 
series, or type, or which were matched to >1 model were excluded. Homografts, autografts, 
rings, valve conduits, two particular model types, off-label procedures, and valves not produced 142 
by one of the UK primary suppliers were also excluded (see Appendix for details). The 5 
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manufacturers included are Edwards Lifesciences (Irvine, CA, USA), Medtronic Inc. 144 
(Minneapolis, MN, USA), Sorin Group (Milan, Italy), St Jude Medical, Inc. (St. Paul, MN, 
USA), and Vascutek Ltd. (a Terumo Company, Inchinnan, Scotland, UK). 146 
Study variables 
For each procedure, data were extracted for administrative factors, patient characteristics, 148 
comorbidities, surgical team, intra-operative factors, and post-operative outcomes. There were 
few missing clinical data (all >95% complete with the exception of the dichotomous creatinine 150 
variable [5.6% missing], critical preoperative state [7.4% missing], haemodynamics [5.1% 
missing] and aortic valve pathology [10.1% missing]). Details of study variable definitions and 152 
missing data imputation are given in the Appendix. 
Study outcomes 154 
The outcome for this study was time from surgery to the first event of death or re-
intervention. Patients were censored at the last follow-up time if alive and re-intervention free. 156 
Patients who died in-hospital on the day of surgery were recorded as having a nominal survival 
time of 0.5 days. Follow-up data, until the point of discharge, were collected by the NACSA 158 
registry and post-discharge survival data were collected by record linkage to the ONS death 
registry. Re-intervention was defined as surgical reoperation on the aortic valve for any reason or 160 
TAVI. Time-to-re-intervention data was collected by intra- and inter-record linkage as described 
above. 162 
Statistical analysis 
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Mechanical and biological valves were analyzed separately to avoid confounding by 164 
indication. Valves were compared only at series-level. The Kaplan-Meier estimator was used to 
construct survival curves for the time-to-event outcome, and compared between valves using 166 
log-rank tests. Multivariable Cox proportional hazards regression models were used to adjust for 
potential differences with zero-mean valve series-level normally distributed random effects. The 168 
exponentiated random-effects—also known as the shared frailties—act multiplicatively on the 
baseline hazard rate and therefore have an intuitive translation: frailty terms >1 correspond to 170 
increased hazard for a valve, and those <1 correspond to decreased hazard. Frailties where the 
corresponding 95% prediction interval lower limit lies above 1 indicate a valve with a 172 
significantly large hazard rate for the outcome. The focus of this study was not the identification 
of prognostic factors, hence we limit reporting to the frailty effects. For comparison, unadjusted 174 
frailties are also reported. All analyses and data cleaning were performed in R (Version 3.3.1; R 
Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/). More 176 
detailed description of the statistical analysis is given in the Appendix. A number of different 
sensitivity analyses were performed (reported in the Appendix). All inferences remained broadly 178 
consistent. 
  180 
 11 
RESULTS 
From 79,345 AVR ± CABG records with a biological or mechanical prosthesis, a total of 182 
54,866 records were retained for analysis (Figure 1; Appendix), from 37 hospitals (including 4 
private units) and 344 consultant surgeons. 184 
Table S1 lists the valves included, which were grouped into 15 and 10 series of 
biological and mechanical valves, respectively. Figure 2 shows an increasing trend in the 186 
implantation rate of biological valves during the study period, stabilising at 86%. Figure 3 shows 
the number of valves implanted by time for each series. The distribution of patient age at surgery 188 
(Figure 4) indicates homogeneity between the valve-series within type (biological and 
mechanical), with the exception of greater patient ages for the Medtronic Hall series, Vascutek 190 
Ultracor series, Edwards Lifesciences Mechanical series, and Sorin Sutureless series relative to 
others of the same type. Plots for logistic EuroSCORE, gender, native valve pathology, 192 
procedure, BMI, valve size, and NYHA grade are shown in Figures S1-S8. 
Valve outcomes 194 
During a median follow-up of 4.1 years (maximum follow-up 15.3-years), 13,104 deaths 
(11,353 biological; 1751 mechanical) were recorded and there were 723 (571 biological; 152 196 
mechanical) re-interventions, (682 were surgical procedures and 41 were TAVIs). Results from 
the Kaplan-Meier estimator analysis and pathological data for surgical re-interventions are 198 
described in the Appendix. 
After adjustment, the random effects survival model indicated that the Sorin Mitroflow 200 
series (frailty 1.19 [95%PI: 1.09 to 1.31]) and Sorin Biological series (frailty 1.18 [95%PI: 1.06 
to 1.32]) displayed larger hazard than expected (Figure 5). To place the outcomes into 202 
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perspective, the 10-year overall freedom from re-intervention or death rates for the 2 valves were 
33.8% [95%CI: 31.3% to 36.5%] and 41.4% [95%CI: 37.6% to 45.6%], respectively, compared 204 
to the overall average of 47.2% [95%CI: 46.2% to 48.1%] for all non-Sorin biological valves. 
Although non-significant, the lower 95% PI for the Medtronic ATS-3f series only marginally 206 
crossed the line of unity (frailty 1.21 [95%PI: 1.00 to 1.47]). For mechanical valves, the 
Medtronic Hall valve had a significantly larger unadjusted hazard (unadjusted frailty 1.48 208 
[95%PI: 1.22 to 1.80]). However, after adjustment this was considerably shrunken (adjusted 
frailty 1.10 [95%PI: 0.97 to 1.24]), reflecting the greater patient age relative to the profile of 210 
other mechanical valves. Additional results are provided in the Appendix 
There were three prosthetic valves with a significant reduction in hazard (Figure 5): the 212 
Edwards Lifesciences Perimount series (frailty 0.88 [95%PI: 0.80 to 0.96]), the Edwards 
Lifesciences Perimount Magna series (frailty 0.88 [95%PI: 0.80 to 0.96]), and the Medtronic 214 
Hancock series (frailty 0.88 [95%PI: 0.78 to 0.98]). 
A subgroup analysis of all bioprosthesis records performed on or after 1st April 2008 216 
(n=23,834) showed that the lower 95% prediction interval limit was <1 for every valve after 
adjustment (see Appendix). 218 
 13 
DISCUSSION 220 
We analysed a comprehensive clinical registry to measure re-intervention-free survival in 
a large series of patients undergoing AVR in the UK. Two series of prosthetic aortic valves were 222 
associated with significantly increased hazards of death or re-intervention, relative to the 
population of prosthetic valves implanted in England and Wales from large suppliers. Similarly, 224 
three series of prosthetic valves were associated with decreased hazards. Inferences remained 
broadly consistent following covariate adjustment and sensitivity analyses. This study has shown 226 
that routinely-collected clinical registry data can be exploited, in conjunction with multifaceted 
record linkage, to perform long-term device surveillance. 228 
There is a large literature examining outcomes following different prosthetic AVR 
implants. Few studies, however, reflect national data. Moreover, the evidence-base is mixed. For 230 
example, some studies have suggested an inferior performance of the Sorin Mitroflow17,18 
whereas on the other hand, others have demonstrated long-term durability and haemodynamic 232 
performance.19,20 
The NHS number–a unique patient identifier—enables record linkage across clinical 234 
registries and other data sources. It would be feasible to exploit this to link across further data 
sources (e.g. trace readmission from administrative data). In fact, strategic linking of 236 
complementary registries and data sources is a “foundational architectural construct” 
recommendation of the US Medical Device Registries Task Force.21 Furthermore, record-linkage 238 
could be further extended using unique serial numbers of implanted devices (including prosthetic 
aortic valves) to device manufacturer databases to improve ongoing research, augment clinical 240 
trial follow-up after completion, and to allow traceability in case of serious fault detection. The 
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planned role out by the US FDA of a unique device identification system integrated for use with 242 
electronic health records would allow scalable cross-speciality surveillance.22 
We explored outcomes in prosthetic valves cross-sectionally using 15-years of data. 244 
Moving forward, this is not a suitable approach for post-market device surveillance, which 
should be dynamic, providing regular updates, to achieve superiority over existing passive 246 
reporting mechanisms. It is conceivable that signals of unexpected patterns of outcomes could 
have been detected earlier on. The Data Extraction and Longitudinal Trend Analysis (DELTA) 248 
network study is a validated example of such a tool, which has utilised propensity score 
matching and statistical process control methodology to evaluate the safety of high-risk 250 
cardiovascular devices for perioperative binary outcomes.13,21,23,24 Similar efforts for post-market 
surveillance of pharmacological products are also on-going.25 Whilst the methodology applied 252 
here was relatively simplistic, what we have demonstrated is that routinely collected clinical 
registry data can be leveraged for evaluating performance of medical devices, even when this 254 
was not a primary goal of the data collection programme. With some improvements to the data 
collection mechanisms, this messy real-world registry, or other registries, data could be analysed 256 
using alternative platforms. 
  258 
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LIMITATIONS 
Data quality 260 
Research with routinely-collected healthcare data inevitably raises questions over data 
quality. Many of the data on clinical variables are of high quality, owing to the fact they are used 262 
for national governance.16,26 Valve-specific data, on the other hand, are not subject to similar 
quality management. As the valve model data were collected as free-text inputs, more data 264 
quality issues were present than for equivalent clinical information collected using structured 
inputs. Data quality is expected to improve in the future, due to increased scrutiny of device 266 
monitoring. Caution must therefore be taken when interpreting the results, as there is potential 
for coding errors by the surgeon. 268 
Valve classification 
Focusing surveillance on a coarsened valve grouping—series—as opposed to valve 270 
models ensured that the maximum number of records would be available for analysis. This 
decision, whilst allowing us to retain more records for analysis, introduces limitations. Firstly, 272 
different models in a series, including stented and stentless models, or different generations of 
the same model, might have a variable effect on outcome. For example, the latest generations of 274 
Sorin Mitroflow valves are processed with a phospholipid reduction treatment to mitigate 
calcification. This might lead to improved performance compared to earlier generations. 276 
Secondly, not all valve series are clearly delineated due to either historical device company 
purchases/mergers or naming conventions. Similarity in naming means that valves identified to 278 
the series level but not the model level might potentially be misclassified. This is discussed 
further in the Appendix. 280 
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Covariate adjustment 
The adjustment data used in this study derives from a national clinical registry, which is 282 
widely accepted to be superior to administrative data.27 There was no a priori expectation of 
gross selection bias by valve series within valve type, nor was substantial heterogeneity 284 
observed, unlike in some other post-market surveillance studies for cardiovascular devices.13 
However, there has been a shift in patient risk profiles over time,28 which might confound with 286 
market availability of certain valves. We adjusted for baseline risk factors, as well for a number 
of clinical valve-related variables, and contrasted the change in inference with that of the 288 
unadjusted model. Another potential source of bias stems from the missing data being imputed 
according to a (gender-stratified) mean/mode approach;29 however, missing data was not 290 
considered substantial. One should also note that the number of random-effects was quite small 
for a frailty model. Additionally, no adjustment for institutional effects were included, which 292 
could conflate with models implanted. 
Study outcomes 294 
In some records, patient ID was missing, which can reduce the ability to track patients. 
Moreover, tracking was terminated at different time points for different endpoints: December-296 
2012 for TAVI, March-2013 for surgical re-intervention, and July-2013 for survival. Since the 
focus of the study was on valve surveillance, rather than patient outcomes monitoring, we only 298 
analysed the time to first event. We also note that sample sizes differed substantially between 
models. This was due to multiple factors, including market availability; some are relatively new 300 
and others have been withdrawn, which might impact on the ability to detect valves that have 
significantly different event hazards.30 Some newer implanted valves may not yet have sufficient 302 
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volume to show significantly different outcomes. We have also defined a composite outcome for 
analysis, rather than analysing death and re-intervention as a competing risk.31 Differences in 304 
outcomes may be attributable to different causes; for example, if a valve migrates it will lead to 
an increase in re-operation, as was observed with the 3f Enable Aortic Bioprosthesis.32 306 
The greatest clinical limitations of this study are its relatively short follow-up and lack of 
other clinical outcomes.33 The median follow-up time was 4.1-years, however valve failure is 308 
most likely to occur later on, especially in the context of mechanical valves. In fact, only 152 
surgical re-interventions were observed in the mechanical valve group. Finally, we excluded 310 
patients who had multiple surgical records within a single admission; however, there were only 
34 such cases satisfying the inclusion criteria for the study. 312 
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CONCLUSIONS 314 
The need for such post-marketing surveillance of medical devices was made clear by the 
PIP breast implant and other medical device scares,3 yet infrastructure is lacking. We have 316 
shown that a national clinical registry, linked to other routinely-collected data, might be used to 
inform post-market  surveillance programmes. By analysing 15-years of data on AVR 318 
procedures in England and Wales we identified 2 prosthetic valves that may warrant further 
scrutiny through additional studies. As Taylor noted about valve monitoring nearly 3-decades 320 
ago, “overreaction is as inappropriate as complacency”.34 Given the limitations of the study, the 
signals shown here should only serve as a hypothesis generating, and not be misinterpreted as 322 
causal effects. 
  324 
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FIGURE LEGENDS 
Figure 1. Flowchart of study data. 456 
Figure 2. Trend in proportion of biological and mechanical valves implanted over the study 
period. 458 
Figure 3. Trends in number of valves implanted by valve series over the study period. 
Figure 4. Box-and-whisker plots of patient age at time of surgery stratified by valve series. 460 
Figure 5. Frailty effects (black filled circles) and 95% prediction intervals (black lines) by valve 
series for time-to-death and time-to-re-intervention as calculated for Cox random effects models 462 
(with and without adjustment for other patient and operative risk factors). Red dashed line 
denotes ‘no effect’. 464 
